Amgen Inc

NASDAQ:AMGNUnited States

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Contact Information

Headquarters

1 Amgen Center DrTHOUSAND OAKS, CA, United States 91320-1730

Phone

805-447-1000

Fax

805-447-1010

Executives

Chairman of the Board, President, Chief Executive Officer

Robert Bradway

Chief Financial Officer, Executive Vice President

Peter Griffith

Executive Vice President, General Counsel, Secretary

Jonathan Graham

Executive Vice President - Human Resources

Lori Johnston

Executive Vice President - Global Commercial Operations

Murdo Gordon